24 January 2024
Oxford PharmaGenesis has contributed to the development of the new ACCORD reporting guideline to help the medical and scientific communities to improve the reporting of research involving consensus methodologies. The guideline was published in the non-profit open access journal PLOS Medicine.
Oxford PharmaGenesis has made its first appointments to the new role of Director of Innovation, created specifically to support teams across the global organization in utilizing new and emerging technology to support their clients’ unmet needs.
Oxford PharmaGenesis has been designated a centre of Excellence in Wellbeing this year by Great Place to Work®. The accolade recognizes organizations with excellent well-being practices and is a welcome acknowledgement of our increasing efforts to foster a culture of openness, empowerment and support in the workplace.
Richard White, COO of Oxford PharmaGenesis, was a panellist at the recent virtual workshop on ‘Artificial intelligence (AI) to accelerate discovery’, hosted by the Friends of the National Library of Medicine (FNLM) and sponsored by Oxford PharmaGenesis. He discussed emerging trends in the use of AI by the pharmaceutical industry, with a focus on how…
Oxford PharmaGenesis has been recognized across offices worldwide with an internationally renowned UK Best WorkplacesTM award. The accreditation is thanks to colleagues who rated the leading independent HealthScience communications consultancy as ‘a great place to work’ in the Great Place to Work® 2021 survey.
Together with Pfizer Inc. and Digital Science, Oxford PharmaGenesis colleagues have co-developed an AI-based literature interrogation tool that will help researchers to identify biomarkers of emerging scientific interest in oncology.
Part-funded by Oxford PharmaGenesis, ‘Our Big MS Adventure’ uniquely shows the impact of multiple sclerosis over 12 years, highlighting breakthroughs in treatment, and sharing emotive personal journeys.
